Orphan Drugs and Rare Diseases

The Orphan Drugs market is set to rise as a result of pharmaceutical companies now looking to orphan drugs as an essential revenue stream with 2014 set to be the year to see Orphan adoption!

As of January 2014, the EMA lifted the restriction on providing fee reductions to large companies developing new orphan drugs and the Early Access to Medicines Scheme was introduced. Key implementation of this will be a factor into further commercialization and developments.

With collaboration being a key topic of discussion, the conference will enable all those involved to discuss Market Access, Pricing and Reimbursement, Patient Engagement and Recruitment, with an insight into Regulatory Requirements.

SMi are providing a platform for all stakeholders, inclusive of small biotechs, pharmaceutical companies, patient advocacy organizations, researchers and regulators to share perspectives and expertise to drive the field of Orphan Drugs and Rare Diseases forward.